TASLY(600535) China Securities·2025-05-21 08:50Investment Rating - The report maintains a "Buy" rating for the company, indicating an expected relative price increase of over 15% [4][23]. Core Views - The company has shown stable revenue growth despite external industry challenges, with Q1 2025 revenue at 2.055 billion yuan, a year-on-year increase of 0.30%. The net profit attributable to shareholders was 314 million yuan, up 6.47% year-on-year, while the net profit after deducting non-recurring items decreased by 19.54% [2][8]. - The company is focusing on enhancing R&D capabilities and modernizing traditional Chinese medicine, with expectations for stable growth in the traditional Chinese medicine sector and new product introductions in chemical and biological pharmaceuticals [1][10][11]. - The strategic integration with China Resources is progressing well, which is anticipated to strengthen the company's competitive position in the market [12]. Financial Performance Summary - For Q1 2025, the company achieved a revenue of 2.055 billion yuan, with a net profit of 314 million yuan. The core pharmaceutical segment generated 1.842 billion yuan in revenue, reflecting a 1.83% increase year-on-year [2][9]. - The company’s gross margin for Q1 2025 was 66.61%, a slight decrease of 0.55 percentage points year-on-year, indicating stable profitability despite pricing pressures [13]. - The forecast for revenue from 2025 to 2027 is projected to be 9.001 billion yuan, 9.539 billion yuan, and 10.129 billion yuan, respectively, with corresponding net profits of 1.074 billion yuan, 1.216 billion yuan, and 1.386 billion yuan, reflecting growth rates of 12.4%, 13.3%, and 14.0% [16].